Array BioPharma announces a 62% observed OS at one year from phase 3 BEACON CRC trial
Array BioPharma announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, binimetinib, and cetuximab in patients with BRAFV600E-mutant metastatic CRC. June 23, 2018